Author Topic: (Abst.) Drug-associated PML in MS patients  (Read 49 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8248
  • MS diagnosed 1980
  • Location: Pacific Northwest
(Abst.) Drug-associated PML in MS patients
« on: July 17, 2018, 02:21:23 pm »
From Multiple Sclerosis Journal, July 9, 2018--"Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients," a study of more than 100,000 MS patients over two years (2015-17).  The researchers conclude:



Quote
The relative risk of PML with natalizumab was much higher than with any of the other DMDs and one with fingolimod followed. One with dimethyl fumarate and rituximab was lesser. Glatiramer acetate, interferon, and dalfampridine were not associated with PML risk based on our analysis.


http://journals.sagepub.com/doi/abs/10.1177/1352458518786075
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
51 Views
Last post May 29, 2016, 04:39:51 pm
by agate
0 Replies
46 Views
Last post June 20, 2017, 03:17:03 pm
by agate
0 Replies
30 Views
Last post June 01, 2018, 02:36:11 pm
by agate
0 Replies
28 Views
Last post June 11, 2018, 07:48:30 pm
by agate
0 Replies
34 Views
Last post April 06, 2019, 03:56:43 pm
by agate